Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article provides contact details and affiliations for Amy M. Karch and Fred E. Karch; it presents no new research findings.

This editorial reviews recent European legal developments related to patents on second medical uses and dosage regimes, with no new research findings reported.

In this study, the safety of finasteride in rats varied depending on dosing time, while its effectiveness on prostate weight reduction remained consistent.

In this study, the safety profiles of four treatments for early rheumatoid arthritis were assessed over one year, and the most serious side effects necessitating treatment discontinuation were noted in the leflunomide group, whereas no such withdrawals occurred in the methotrexate plus prednisolone group.

This review discusses the use of anabolic-androgenic steroids in sports and outlines current methods for detecting urinary steroid doping, particularly testosterone, but reports no new experimental findings.

This article reviews the conflicting approaches to patentability of dosage regimen inventions under Chinese law and reports no resolution on which position Chinese courts will adopt.

In this review, the researchers found no statistically significant difference in overall survival and disease-free survival between busulfan/cyclophosphamide and total bone irradiation conditioning regimens for acute myeloid leukemia patients.

This study models the pathways of nandrolone and its metabolites in the body and suggests methods to counteract finasteride's role in enabling PED users to cheat drug tests.

In this study, bicalutamide at low doses was not linked to significant liver enzyme changes compared to other androgen-blocking treatments in transfeminine adolescents and young adults, suggesting its safety with careful monitoring for this population over one year.

This review discusses the legal status of patents for treatment and dosage regimes under the Patents Act 1977 and EPC 2000, highlighting ongoing uncertainties in their availability.

This narrative review concludes that long-term randomized controlled trials are needed to establish clear guidelines for testosterone therapy in women, given the lack of FDA-approved formulations and the variable quality of current treatments.

The UK High Court revoked Lundbeck's patent for Escitalopram, and second medical use claims based on dosage were not considered novel.

In this study, conducted during the 22nd FIFA World Cup in Qatar, doping control analysis of 1612 samples showed negative results for prohibited substances, except for two instances each of codeine and carboxy finasteride.

This review discusses the profound impact of obesity on skin physiology and dermatologic conditions and reports no new experimental results, recommending awareness and treatment strategy development for obesity-associated dermatoses.

This systematic review found that hair loss was more frequently observed in acne patients on isotretinoin doses ≥0.5 mg/kg/d compared to those on lower doses, suggesting dose-dependent effects.

This study found that patients, oncologists, and payers prioritize a significant improvement in efficacy to justify the added risks and costs when considering CDK4/6 inhibitors combined with endocrine therapy for early-stage breast cancer.

This commentary discusses current challenges and future opportunities in pharmaceutical care for organ transplant recipients, focusing on immunosuppressive strategies, their complexities, and potential advancements like nanoimmunotherapy, but reports no new clinical results.

This source provides a comprehensive guideline for the management of transgender individuals in India, highlighting the need for multidisciplinary diagnosis, counseling for gender-affirming hormone therapy, and the importance of addressing social stigma, legal issues, and medical training to improve healthcare access for this population.

Managing skin diseases during pregnancy and postpartum requires careful consideration of treatment safety and dosing to protect both mother and baby.

This study found that a three-month regimen of leucoselect phytosome, a grape seed extract complex, was well tolerated and significantly reduced bronchial proliferation markers in heavy active and former smokers.

This study found that while the carboplatin-paclitaxel regimen for advanced lung cancer is more affordable than newer treatments and maintains a good performance status, it significantly increases risks of alopecia and peripheral neuropathy.

The document concludes that there are still unknowns about the effectiveness, risks, and detection of performance-enhancing drugs, and doping remains a challenge.

This review discusses the relevance of human androgen receptor action in sports doping and examines the potential of cell-based biological assays for detecting androgenic anabolic steroid use, without presenting new research findings.

This review discusses recent advancements in female contraception and covers topics like adapted regimens, non-invasive sterilization, and the promise of new methods, but it reports no new clinical findings.

This paper reviews the role of pharmacokinetic/pharmacodynamic modeling in drug development, emphasizing its application for drug dosing guidance, safety resolution, and therapeutic monitoring improvement, without presenting new clinical results.

This review discusses the promising role of JAK inhibitors in managing alopecia areata, reporting significant hair regrowth and acceptable safety profiles but noting the need for further research on dosing and long-term safety.

This study found that 95% of untreated advanced-stage follicular lymphoma patients responded to a single course of the Bexxar regimen, with 75% achieving complete remission and remaining disease-free for years.

This review outlines strategies for preventing, identifying, and managing complications related to current MS therapies and reports no new clinical results, emphasizing the growing complexity in MS treatment regimens.

In this case report, a three-generation family with Gorlin-Goltz syndrome showed a heterozygous PTCH1 splice-donor variant associated with the disease, and two affected relatives benefited from individualized, side-effect-guided dosing of the drug sonidegib, experiencing regression of basal cell carcinoma lesions.